BioMarin doses first patient in Phase 1/2 trial with BMN 190 BioMarin Pharmaceutical announced that it has dosed the first patient in the Phase 1/2 trial for BMN 190, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with neuronal ceroid lipofuscinosis type 2, a form of Batten disease. This is the first time that a patient with Batten Disease has been treated with an enzyme replacement therapy in a clinical trial setting.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link